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Introduction
Nowadays, advances in technology and the as-
sociated increase in the standard of living has lead
to a decrease in physical activity and the consump-
tion of processed, high salt foods. As a result, there
has been an increase of civilization diseases. Mor-
bidity related to obesity, vascular hypertension,
coronary artery disease, diabetes mellitus, chronic
heart failure and neoplasma has increased in the
population.
Type I or type II diabetes mellitus leads to con-
gestive heart failure and inversely, primary heart
failure leads to insulin resistance and finally to the
development of the type II diabetes mellitus. Dia-
betes mellitus along with metabolic disorders con-
tribute to the damage of the majority of organs.
Dynamic energetic reactions taking place in the my-
ocardium are disordered. The main source of ener-
gy for a cardiomyocyte changes from glucose to free
fatty acids (FFA). FFAs start a cascade of processes
that damage the myocardium. The result is diabet-
ic cardiomyopathy. Diabetic cardiomyopathy, along
with hypertension and coronary artery disease
constitute a “cardiotoxic triad”. All the diseases, in-
dependently, influence anatomy, function and bio-
chemistry of cardiomyocytes [1].
Patients with an early diagnosis of diabetes
mellitus, as well as of asymptomatic heart failure,
adequate control of glycaemia and an early applica-
tion of pharmacoteraphy can reduce unfavourable
cardiac remodeling and decrease the progression of
myocardial disorder [1].
The definition of diabetic cardiomyopathy
Diabetic cardiomyopathy has been described
for the first time 25 years ago [2]. The term “cardio-
myopathy” was described as the sum of disorders
caused by the influence of diabetes on heart function
and structure. Those disorders include: coronary
macroangiopathy (double increase in prevalence
and progression of coronary arterial atheromatosis),
increased prevalence of hypertension, heart micro-
angiopathy (that is degeneration of small coronary
arteries and capillaries, caused by accumulation of
glycoprodeids in the vessel wall and by prolifera-
tion of endothelium). There is also the autonomic
heart neuropathy present, as well as metabolic and
biochemical disorders in the cardiomyocytes, and
myocardial steatosis in uncontrolled diabetes [3–5].
Macroangiopathy that occur in diabetic patients
is the structural basis of ischeamic heart disease.
Diabetic cardiomyopathy is caused by primary bio-
chemical damage, highly related to diabetes and
microangiopathy of myocardial supply vessels.
The concept of diabetic cardiomyopathy in-
cludes degenerative myocardial damage, as a result
of metabolic changes in cardiomyocytes, and pathol-
ogy of small vessels [3–5]. Diabetic cardiomyopa-
thy is characterized as a decrease in heart systolic
function which leads to congestive heart failure [6].
The coincidence of cardiomyopathy with small
vessel disease or cardiovascular neuropathy cannot
be excluded. Myocardial metabolic disorders in-
clude: changes in energetic pathways of the heart,
structural changes of collagen fibers and contrac-
tile proteins, as well as vascular disorders that lead
to impaired perfusion. The result of the changes
mentioned above and increased fibrosis are stiffness
and lack of compliance [3, 6].
The symptoms of circulatory failure in diabetic
patients may occur either with heart enlargement
(the disturbances in blood supply ma be the cause
of myogenic heart dilation in diabetes), or without
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cardiomegaly, as so called small stiff heart syn-
drome in diabetes [3–5].
In diabetic patients with type I and II diabetes
with accompanying coronary heart disease, with
significant myocardial hypertrophy, without arteri-
al hypertension, it often comes to myocardial inf-
arction, with heart failure as a complication. In
a small percentage of patients symptoms of cardiac
failure may occur without ischaemic heart disease,
heart infarction or arterial hypertension.
In both cases, at first it comes to a functional
heart dilation with increase in late-diastolic and late-
systolic blood volume in the ventricles, and then to
myocardial hypertrophy. An obstruction in blood
flow through a certain area of coronary arterial sup-
ply results in a quick increase in force of contrac-
tion in the remaining, adequately supplied areas of
heart muscle. In diabetic patients with coronary
heart disease and cardiac failure comes to dyssyn-
ergy of muscle fibers during heart systole. The ef-
fect of this dyssynergy and heart dilation is in-
creased energy use (oxygen) per each heartbeat in
correctly supplied heart muscle fibers. When large
left ventricular infarcts are present, and also in post-
infarction aneurysm, it comes to hypertrophy of the
remaining, well supplied areas. During the process
of myocardial overgrowth the arteries, arterioles
and capillaries dilate. Their walls thicken, and if they
are not capable of proportional dilation and increase
in function, myocardial hypertrophy may be halted.
The occurence of diabetic microangiopathy hampers
the growth of coronary capillaries. This results in
faster degeneration of the hypertrophied myocar-
dium and in the beginning of heart failure.
The small stiff heart syndrome is a term refer-
ring to the failure of a heart that is not enlarged. It
may occur in the syndrome of massive atheroscle-
rosis in 2 or 3 coronary arteries in patients after
myocardial infarction. Major fibrosis of the  heart
prevents its dilation. Diastolic heart compliance is
also restricted by areas of focal hypertrophy. The
changes mentioned above, due to the extent of
atheromatosis and its coincidence with small ves-
sel pathology, occur in patients with long-lasting
diabetes. Often the first signs of cardiomyopathy are
those of heart failure [4, 5].
Heart volume in radiography in those patients
is normal. In echocardiography segmental dyskine-
sis and traits of diastolic left ventricular failure are
found. Decreased heart compliance is characteris-
tic. In cardiomyocytes of some patients, besides
muscle hypertrophy, increased collagen hyperpla-
sia is found. Fibrosis with focal hypertrophy is the
cause of decreased compliance and increased
collagen volume in diabetic patients. It is believed
that focal ischaemia without preceeding hypertro-
phy may cause degeneration or atrophy of the myo-
cardium [4, 7].
Epidemiology
It has been shown in the past few years that
heart failure is an individual risk factor in the de-
velopment of type II diabetes. It was observed in
the Italian CAMPANIA study that in the elderly
population, in 3-year observation period, diabetes
has developed in 29% of patients with diagnosed
heart failure, compared to 18% in the control group
[8]. It has been proved that heart failure significantly
worsens the prognosis of diabetic patients. Diabet-
ic patients are the group of the highest risk of de-
veloping chronic heart failure [1].
Epidemiological data from the Framingham
study shows, that heart failure is 5 times more com-
mon among diabetic women and 2 times more com-
mon in diabetic men than it is in non-diabetics of
the same age [1, 9].
Yearly incidence of heart failure in diabetic
patients is ca. 3.3%. Aronow et al. [10] stated that
in 12% of type II diabetic patients heart failure is
found. The results of research on diabetes incidence
in the population of chronic heart failure patients
vary significantly due to type of research, patient’s
age, progression of disease, and the definition of
diabetes [11].
In diabetic population, both type I and II, a de-
crease in left ventricle was found in ca. 50% of pa-
tients. Also in young diabetics the decrease in left
ventricular diastolic function was found [12].
According to echocardiography of diabetic pa-
tients, there was a constant progression found, from
asymptomatic decrease in diastolic function,
through symptomatic diastolic function decrease, to
significant decrease in ejection fraction [13].
Etiology
Risk factors of developing diabetes, such as
obesity, lack of physical excercise, are also the risk
factors of cardiovascular diseases, including heart
failure. Moreover, in type II diabetics are other tra-
ditional cardiovascular risk factors present: arterial
hypertension, coronary atheromatosis, dyslipi-
demia. Their occurence does not fully explain great-
er prevalence of heart failure. The reason of this
lies in common pathomechanisms on the cellular
level, occuring in different phases of glucose into-
lerance and insulinresistance [14, 15].
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Myocardial energy metabolism
in physiology and in diabetes
Physiologically, glucose metabolism plays
a significant role in the heart. It is the basis of ionic
pump activity, it is responsible for sustaining the
cardiomyocyte membrane potential and for quick
calcium ion transport between cellular compart-
ments. Glucose oxidation pathways require less
oxygen per mole of produced ATP than the free
fatty acid pathways (FFA). Consequently, in myo-
cardial ischaemia, pressure overload, the glucose
and lactate become the basic energy source, and
glucose uptake may increase up to 30 times [16].
FFAs are an energy source, basic membrane com-
pound, mediators of signal transduction (among oth-
er the initiators of apoptosis), ligands of nuclear
transcription factors (PPAR-a).
Complex glucose and FFA metabolism path-
ways are responsible for ionic pump function and
permeability of cellular membranes. Additional
pathways related to those transformations influence
the activity of cytoskeletal proteins and enzymes
and gene expression.
Toxic influence of hyperglycaemia and glyca-
tion of heart proteins are, among others, major
mechanisms resulting in structural and functional
damage of cardiomyocytes [5].
Metabolic factors in diabetic patients have a
major influence on the function of the myocardium
and the whole circulatory system. In diabetic pa-
tients the glucose metabolism in the heart is insuf-
ficient, what results in increased energy production
from FFA b-oxidation pathways. Change of  the
oxidation substrate from glucose to free fatty acids
is a major cause of pathology because the FFAs
damage the myocardial function.
The levels of insuline, FFAs and glucose are
increased in type II diabetics.
It has been proved in experimental research on
animal models that the levels of glucose transport-
er mRNA are decreased, which results in the de-
crease of protein expression and impaired glucose
transport into the cardiomyocytes. Consequently,
non-oxidative glycolysis and lactate acidosis in-
crease. Under those circumstances, cellular and
intercellular calcium transport is decreased, what
causes progression of left ventricular dysfunction,
even in the absence of ischaemia. Physiological
mechanism of increasing contractile function and
lactate uptake under adrenergic stimulation, ade-
quate to increased loading, is not observed in the
myocardium of diabetic patients. In the heart of
a diabetic patient there is a decrease in the ability to
oxidate glucose and lactate, secondary to decreased
ability to oxidate pyruvate by the mitochondria [14].
Increased lactate production and overloading of the
cardiomiocytes with calcium ions, contribute to car-
diomyocyte apoptosis and consequently to impair-
ment of myocardial function [14].
Pyruvate oxidation rate depends on, among
others, on the substrate and product levels in the
mitochondria. Increased level of acetylcoenzyme A
and FFA observed in diabetic patients suppresses
pyruvate metabolism through inhibition of pyruvate
dehydrogenase, what impairs glucose oxidation [17].
Additionally the level of triglicerole is increased
in the myocardium of diabetic patients. Metabolism
disturbances in the heart of diabetic patients impair
the adaptation to ischaemic or overload condition.
At first the heart adapts to altered energetic condi-
tions through increased expression of genes cod-
ing proteins that take part in FFA metabolism, what
increases the availability of the FFAs and allows use
of their energy. However, progression of diabetes and
additional damaging factors, such as arterial hyperten-
sion lead to failure of adaptive mechanisms. FFA re-
dundance cannot be transported to the mitochondria
and be used by the heart, what leads to increase in
cytoplasmatic acetylcoenzyme A level. Their utiliza-
tion is performed through diacylglycerole and cera-
mide synthesis. Diacylglycerole causes permeability
disturbances of cardiomiocyte membrane, through
chronic activation of b-protein kinase C isoforms. This
causes the insulin resistance and occurrence of con-
traction disorders. The expression of C-b2 protein
kinase in the miocardium leads to the development
of cardiomyopathy [5].
Both FFA and chronic hyperglicaemia increase
the production of free oxygen radicals, the presence
of which results in the impairment of cellular
metabolism. They impair the function of contractile
and enzymatic proteins, as well as of endothelial
regulators. It comes to disturbances in ionic chan-
nel function, calcium homeostasis, activity of tran-
scription agents that bind to DNA, as well as to the
initiation of apoptosis [18]. Additionally, high concen-
trations of FFAs  increase sympathetic activity.
Beta-oxidation of FFAs may be suppressed by
glucose. As a result of hyperglicaemia and high FFA
concentration it comes to increased deposition of
lipids in cardiomyocytes, what results in heart func-
tion impairment. In cardiomyocytes of diabetic pa-
tients there was an accumulation of intermediate
glucose metabolism products found, what is the
result of decreased availability of glucokinase and
inhibition of phosphofructokinase and pyruvate de-
hydrogenase activity, due to increased FFA level
and intracellular lipids overload.
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The glycation of proteins that take part in in-
suline signal transduction under the conditions of
increased glucose concentration induces insuline
resistance [11]. Deposition of the so called advanced
glycation end-products disturbes the balance be-
tween oxidation and reduction in endothelial cells,
leading to oxidative stress [14].
Toxic products of FFA metabolism cause
decrease of sarcoplasmatic calcium pump, blocking
ATP-dependent potassium channel and NaK
ATP-asis activity impairment. It comes to impair-
ment of the calcium outflow from the cardiomyo-
cytes during diastole. Decreased Mg inflow and loss
of potassium ions is observed [5]. Insulin deficien-
cy impairs NO production, and insulin resistance
inhibits vasodilatation caused by NO [5].
Metabolism impairment and insuline resistance
occurring in diabetic patients are both cause and
result of diabetic cardiomyopathy. It was observed
that heart failure may be the cause of insulin resist-
ance that impairs myocardial function [15].
Insulin resistance in primary heart failure devel-
ops as a result of epithelial dysfunction and decrease
in blood flow in skeletal muscles. Heart failure is
a condition decribed as a “storm” of inflammation
markers.
Cytokines circulating in the blood of the patients,
such as for instance TNF-a contribute to insulin re-
sistance and type II diabetes development [19].
Impairing vascular endothelium function in
patients with insulin resistance or with diabetes con-
tributes to repetitive ischaemia and worsening of
miocardial function. This process leads to greater
vascular permeability, and as a result to interstitial
oedema, fibrosing and myocardium dysfunction.
In diabetic patients decreased angiogenesis
was observed, which may also cause damage of the
miocardium [11, 20].
It comes to destructive changes in interstitial
collagen, what is influenced by glication [7]. In-
creased sympathetic activity, decreased mass of
skeletal muscles, fatigue, lower level of physical
activity deepen changes in metabolism typical for
diabetes, contributing to development of a “vicious
circle” and progression of heart failure as well as
insulin resistance [11, 21].
Activation of neurohormonal system
Extension of the ventricles and increase in left
ventricular wall tension result in activation of sym-
pathetic system as well as the renin–angiotensin–
–aldosterone system. Hyperglycaemia has similar
influence on neurohormonal system. At first, this
condition is an adaptation to altered circumstanc-
es, in order to prevent tissue hypoperfusion.
As a result of myocardial hypertrophy and re-
modeling, the volume and shape of the ventricles
change. Then it comes to accelerated apoptosis of
the cardiomyocytes. Heart function impairment
deepens, resulting in increased neurohormonal ac-
tivation [11]. With time it comes to breakdown of
the compensation mechanism and the development
of symptomatic heart failure [19].
It comes to the induction of fetal gene pro-
gramme and to disturbed signal transduction in
b-adrenergic receptors, what induces carnitine
palmitoilotransferase I and increases the use of
FFAs in the myocardium.
Overuse of the FFAs causes inhibition of mem-
brane ATP-ase, what increases oxygen requirement,
leading to ischaemia, myocardial function impairment
and occurence of heart rhythm disturbances. Cardio-
protective activity of b-adrenolytic drugs is based
probably, among others, on inhibition of carnitine
palmitoilotransferase I activity [11].
Alterations in gene expression
The hearts of diabetic patients show several
similarities to the fetal heart fetal. It is caused by
adaptation to hyperglycaemia and the presence of
FFA’s metabolism products. In the myocardium of
diabetic patients it comes to  reexpression of genes
— the activity of genes characteristic to fetal peri-
od increases, what is initially beneficial  in terms
of sustaining systolic function. The accumulation of
intermediate products of glucose metabolism, as
a result of dissociation between glycolysis and pyru-
vate oxidation, in hyperglycaemic conditions result
in activation of glucose-related transcription agents.
Disturbance in signal transduction in b-adrenergic
receptors also results in altered gene expression.
It comes to a-actine gene induction, which is
characteristic for skeletal muscles and is not found
in healthy heart muscle after birth. In diabetic
patients the expression of various myosine chains
alters in the myocardium. It comes to lowering of
the concentration of the quick isoform of heavy
a-chains and increase in free fetal b-isoform. The
level of glucose probably influences the regulation
of the processes mentioned above [22, 23].
The activity of sarcoplasmatic reticulum Ca2+
ATP-ase (that is the sarcoplasmatic calcium pump,
an inotropic protein) is decreased. The result of
those changes is initially decreased ability to relax
and eventually impaired systolic and diastolic fun-
ction [24].
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Prognosis
Hyperglycaemia and diabetes significantly
worsen the prognosis of a patient with chronic heart
failure. The Rotterdam study showed that diabetes
influences overall mortality in a similar manner as
left ventricular dysfunction does [25]. Patients hav-
ing diabetes coexisting with heart failure second-
ary to coronary heart disease have a much higher
overall mortality [26].
It was observed in the SOLVD and RESOLVD
studies that diabetes is an independent mortality risk
factor in patients with lower ejection fraction and in
patients with heart failure [27, 28]. However in dia-
betic patients the cardiovascular complications, in-
cluding heart failure, are the major cause of death,
especially in women and in elderly population [14].
Diagnosis and treatment
The diagnosis of symptomatic heart failure is
not very difficult. A detailed anamnesis, physical
examination, ECG, RTG and transthoracic echocar-
diogram evaluation is essential. However, diagnos-
ing an asymptomatic diastolic and/or systolic dys-
function is a real challenge. In this case, determi-
nation of NT-proBNP peptide or BNP in patient’s
blood and detailed echocardiography is useful.
A study conducted by Epshteyn et al. [29] showed that
in diabetic patients determination of the BNP may
reliably confirm or exclude left ventricular dysfunc-
tion. BNP concentration, unlike ANP concentration,
does not change with glucose concentrations [11].
In the treatment of diabetic patients with co-
existing heart failure correct glycaemia control and
selection of drugs that do not increase glucose
metabolism impairment are essential.
It was proved that better metabolic control in
type II diabetes treated with insuline contributes
to better left ventricular diastolic function and in-
crease in microvessel perfusion reserve [30]. Ac-
cording to those findings, the loop diuretics are rec-
ommended, because thiazides have a disadvanta-
geous influence on glucose metabolism.
A significant decrease in mortality was ob-
served after introducing angiotensin corverting
enzyme inhibitors to therapy. Drugs from this group
may lower insulin resistance and cause hypoglycae-
mia as a consequence [31, 32].
In experimental work, use of etomoxir, an FFA
b-oxydation inhibitor, has resulted after 3 months
in a signficant increase in left ventricular ejection
fraction and maximum ejection volume in physical
excercise [33]. The activity of this drug is explained
by increasing glucose oxidation and decreasing in
SERCA2a expression caused by diabetes and vo-
lume overload [33].
Trimethazidine increases glucose use in the
heart, inhibiting a key FFA mitochondrial uptake
regulatory enzyme, that is carnitine palmitoilotrans-
ferase I. In TRIMPOL-1 study a significant increase
in physical efficiency was proved [34].
Beta-adrenolytic drugs prevent cardiotoxic
sympathetic activation. In diabetic patients a chronic
sympathetic activation occurring in heart failure is
additionally increased by insulin resistance and
hyperinsulinaemia. This results in fetal gene reex-
pression and myocardial remodeling. Beta-adreno-
lytic drugs reverse heart remodeling and improve
left ventricular systolic function. Moreover, they
have beneficial effect on metabolism of the myocar-
dium, they lower FFA use together with increase
in glucose oxidation, and significantly reduce risk
of death. The results of studies on carvedilol and
metoprolol support the use of those drugs in all
patients with stable heart failure, if no absolute con-
traindications are present, especially in diabetic
patients [7, 11, 35–37]. However, application of
b-adrenolytic drugs may make it more difficult to
diagnose hypoglycaemia. This problem may be rath-
er irrelevant with the 3rd generation drugs.
Carvedilol does not influence insulin sensitivity and
glucose accessibility. It causes peripheral vessel
dilatation, increase HDL cholesterol concentration
and lowers triglyceride concentration [38, 39].
Diabetic versus primary cardiomyopathy
An important etiological factor of primary car-
diomyopathy is probably the small vessel disease.
It is believed that most of the “undefined” cardio-
myopathies is a result of inherited tunica media
necrosis in the small coronary arteries [4].
In patients with long-lasting diabetes comes to
cardiomyopathy which is a result of specific degen-
erative changes in small coronary arterioles and
capillaries, as a result of autonomic heart neuropa-
thy and metabolic-derived myocardial fiber damage.
Changes observed in these patients are of mixed
character, and are usually a result of both microan-
giopathy and macroangiopathy. This may result in
hampering of heart hypertrophy. As a result it
comes to a cardiomyopathy called “small heart syn-
drome”, with decreased diastolic compliance.
A second form of diabetic cardiomyopathy is myo-
genic heart enlargement (cardiomegaly). The mecha-
nisms described above in diabetic patients contribute
to greater incidence of chronic congestive heart
failure and are also the cause of variable course of
diabetic cardiomyopathy [4, 5].
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